American Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-2,577,470
| Closed | -$55.9M | – | 84 |
|
|
2017
Q2 | $55.9M | Buy |
2,577,470
+420,100
| +19% | +$7.62M | 3.61% | 5 |
|
|
2017
Q1 | $30.3M | Buy |
2,157,370
+777,853
| +56% | +$12.7M | 2.14% | 18 |
|
|
2016
Q4 | $25.9M | Buy |
1,379,517
+7,007
| +0.5% | +$119K | 2% | 17 |
|
|
2016
Q3 | $22.7M | Buy |
+1,372,510
| New | +$20.3M | 1.74% | 21 |
|
|
2016
Q2 | – | Sell |
-1,303,500
| Closed | -$19.9M | – | 172 |
|
|
2016
Q1 | $19.9M | Buy |
1,303,500
+122,230
| +10% | +$1.92M | 1.74% | 21 |
|
|
2015
Q4 | $23.4M | Buy |
1,181,270
+163,790
| +16% | +$3.11M | 2.08% | 15 |
|
|
2015
Q3 | $17.7M | Buy |
1,017,480
+24,200
| +2% | +$493K | 1.84% | 22 |
|
|
2015
Q2 | $20.1M | Sell |
993,280
-4,010
| -0.4% | -$77.4K | 1.91% | 21 |
|
|
2015
Q1 | $17.6M | Sell |
997,290
-21,630
| -2% | -$369K | 1.73% | 22 |
|
|
2014
Q4 | $16.6M | Buy |
1,018,920
+139,020
| +16% | +$2.55M | 1.8% | 23 |
|
|
2014
Q3 | $19.4M | Sell |
879,900
-41,600
| -5% | -$852K | 2.26% | 16 |
|
|
2014
Q2 | $18.5M | Buy |
921,500
+22,050
| +2% | +$373K | 2.08% | 18 |
|
|
2014
Q1 | $16.7M | Sell |
899,450
-46,700
| -5% | -$643K | 1.97% | 17 |
|
|
2013
Q4 | $9.54M | Buy |
946,150
+170,150
| +22% | +$2.06M | 1.18% | 27 |
|
|
2013
Q3 | $10M | Buy |
776,000
+25,000
| +3% | +$308K | 1.34% | 23 |
|
|
2013
Q2 | $8.91M | Buy |
+751,000
| New | +$8.14M | 1.34% | 25 |
|
Other funds holding AMRI
American Capital Management's AMRI Position: Q3 2017 in Review
American Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 2,577,470 shares — an estimated $55.9M sold.
American Capital Management first reported a position in AMRI in Q2 2013 and held it in 16 quarters. The position peaked at $55.9M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- American Capital Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- American Capital Management sold 2,577,470 Albany Molecular Research Inc shares in Q3 2017, an estimated $55.9M.
- American Capital Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 16 quarters.
- American Capital Management's Albany Molecular Research Inc position peaked at $55.9M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on American Capital Management's 13F filing for Q3 2017, filed 20 Oct 2017.